X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-full-approval-abbvies-ovarian-cancer-therapy-2024-03-22/
https://www.reuters.com/markets/deals/abbvie-buy-immunogen-101-billion-boost-cancer-drug-portfolio-2023-11-30/
https://www.onclive.com/view/maintenance-mirvetuximab-soravtansine-plus-bevacizumab-under-exploration-in-fr-ovarian-cancer
https://www.clinicaltrialsarena.com/news/immunogen-top-line-ovarian-cancer/
https://investor.immunogen.com/news-releases/news-release-details/elaherer-demonstrates-overall-survival-benefit-phase-3-mirasol
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.pharmaceutical-technology.com/news/fda-immunogen-ovarian-cancer-adc/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310
https://www.fiercebiotech.com/biotech/immunogens-phase-3-adc-survival-data-spooks-investors-sending-stock-down-ahead-fda-filing
https://investor.immunogen.com/news-releases/news-release-details/immunogen-present-full-results-soraya-trial-mirvetuximab
https://www.biospace.com/article/immunogen-eyes-2022-approval-for-ovarian-cancer-drug-after-posting-positive-results-in-phase-iii-trial/?s=71
https://endpts.com/news-briefing-abbvie-and-roches-venclexta-scores-another-fda-ok-immunogen-scores-china-deal-with-40m-cash/
https://endpts.com/immunogen-maps-new-path-to-accelerated-approval-biontech-scores-e50m-funding-from-european-bank/
https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial?utm_source=internal&utm_medium=rss
https://www.biospace.com/article/releases/immunogen-announces-completion-of-operational-review-/?s=75
https://www.reuters.com/article/us-immunogen-study/immunogen-drug-fails-cancer-study-shares-slide-40-percent-idUSKCN1QI4FQ
https://www.fiercebiotech.com/biotech/crunch-time-for-immunogen-as-phase-3-readout-looms-for-lead-adc
https://www.biospace.com/article/cp8r-tesaro-highlights-benefits-of-maintenance-therapy-zejula-during-ovarian-cancer-awareness-month/
Market Place
Share 
